Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience

Tarih
2021
Yazar
Bektas, Fatih
Sadri, Sevil
Keskin, Dilek
ÖZGÜR YURTTAŞ, Nurgül
ELVERDİ, Tuğrul
SALİHOĞLU, Ayşe
AR, Muhlis Cem
ÖNGÖREN, Şeniz
BAŞLAR, Zafer
Aydin, Yildiz
Soysal, Teoman
EŞKAZAN, Ahmet Emre
Ozmen, Deniz
ÖZTAŞ, Mert
Bayraktar, Esref Alperen
Üst veri
Tüm öğe kaydını göster
Özet
We retrospectively compared the efficacy and safety of frontline imatinib between elderly patients (>= 60 years old) and younger patients ( <60 years old) with chronic myeloid leukemia (CML). Response rates were similar in both groups. Event-free survival was comparable, and overall survival-when non-CML-related deaths were censored-was also similar. Age at diagnosis and the Charlson comorbidity index were significantly associated with overall survival. In the era of tyrosine kinase inhibitors, survival of patients with CML is determined more by comorbidities than by the disease itself.
Bağlantı
http://hdl.handle.net/20.500.12627/172029
https://doi.org/10.1016/j.clml.2021.04.005
Koleksiyonlar